Trials like ODYSSEY, PROFICIO, FOURIER, SPIRE, ORION-1, 2, and 3 studied the lipid-lowering effect of PCSK9 inhibitors in the general population and even CKD patients, but none of the trials included ESKD patients on dialysis [72,73,74,75,76,77,78,79,80,81]. The gene discussed is PCSK9; the disease is chronic kidney disease.